TIM-3 Suppresses Anti-CD3/CD28-Induced TCR Activation and IL-2 Expression through the NFAT Signaling Pathway
Brian Tomkowicz(Morphotek (United States)), Timothy J. McCabe(Springhouse), Michael Naso(Century Therapeutics (United States)), Sandy Santulli-Marotto(Springhouse), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Eileen S. Walsh(Janssen (Switzerland)), Fred M. Kaplan(Thomas Jefferson University), Nina Chi-Sabins(Springhouse), Jill M. Mooney(Springhouse), Chen‐Ni Chin(Springhouse), Russell B. Lingham(Springhouse), Adam Cotty(Springhouse)
Cited by 80
Related Papers
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy
|BioDrugs|2017|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k
A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
|Blood|2020|167
Kinesin Spindle Protein (KSP) Inhibitors. 9. Discovery of (2<i>S</i>)-4-(2,5-Difluorophenyl)-<i>N</i>-[(3<i>R</i>,4<i>S</i>)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-<i>N</i>-methyl-2-phenyl-2,5-dihydro-1<i>H</i>-pyrrole-1-carboxamide (MK-0731) for the Treatment of Taxane-Refractory Cancer
|Journal of Medicinal Chemistry|2008|157